Pulike secures new registration for triple-action feline vaccine

Pulike Biological Engineering Co., Ltd. (SSE:603566), in collaboration with its subsidiaries Luoyang Huizhong Biotechnology Co., Ltd. and Luoyang Huizhong Animal Protection Co., Ltd., has received a new veterinary drug registration certificate for its "Feline Panleukopenia, Calicivirus, and Rhinotracheitis Trivalent Inactivated Vaccine (strains 708+60+64)." This new Class III veterinary drug was approved by the Ministry of Agriculture and Rural Affairs and publicly announced on September 29, 2025. The vaccine aims to prevent feline panleukopenia, calicivirus, and rhinotracheitis, with an immunity period of 12 months following the second vaccination.

The vaccine, administered subcutaneously, is for healthy cats aged eight weeks and older, with a primary dose of 1ml followed by a booster three weeks later, and then annually. Cumulative R&D expenditure for this product has reached CNY 8.0317 million. This development enhances Pulike's pet product portfolio and strengthens its position in the animal vaccine market.

The company highlighted several advantages of the vaccine, including the selection of clinically effective vaccine strains that match domestic prevalent strains, optimal antigen ratios for maximum immune efficacy, a sustained immunity period of at least 12 months, and the use of an aqueous adjuvant to reduce side effects. Before market launch, the product still needs to obtain a veterinary drug product approval number from the Ministry of Agriculture and Rural Affairs.